ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1474

Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE

Erik Anderson, Chris Tang, An Vo, Cynthia Aranow, Bruce Volpe, Betty Diamond and Meggan Mackay, Feinstein Institutes for Medical Research, Manhasset, NY

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Cognitive dysfunction, Neuroimaging, Neuropsychological Assessment, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Stimulation of the kynurenine/tryptophan pathway by interferons alpha and gamma, both known contributors to SLE pathogenesis, leads to a potentially neurotoxic imbalance of pathway metabolites quinolinic acid (QA), a NMDA receptor agonist, and kynurenic acid (KA), a NMDA receptor antagonist. Elevated QA/KA ratios are implicated in pathogenesis of cognitive dysfunction (CD) in neurodegenerative diseases [1], including SLE.[2] Using FDG-PET and diffusion tensor MRI (DTI) we previously demonstrated brain regions with abnormal increased or decreased metabolism and clusters of decreased white matter structural integrity (WMI), respectively, in SLE compared to healthy controls (HC).[3] Imaging data from a subset of these SLE and HC were analyzed with serum QA/KA ratios and cognitive testing to determine associations between QA/KA ratios and brain structure and function.

Methods: Brain imaging data from 14 SLE and 5 HC subjects were analyzed with serum metabolite levels (measured with high-performance liquid chromatography with mass spectrometry) and cognitive testing (assessed with the Automated Neuropsychological Assessment Metrics) obtained within 2 years of imaging except 2 SLE where the interval was 4 years. SLE subjects met ACR criteria, had low disease activity and corticosteroid doses (Table) and no history of CNS insult. Individual mean fractional anisotropy (FA) values for 6 previously identified abnormal WM clusters and mean metabolic values for previously identified abnormal regions were measured, and WM pathways were constructed between regions with reduced FA, as previously described [3]. Differences between SLE and HC were assessed using t-tests. Correlations between QA/KA and metabolism and FA were assessed with Pearson’s or Spearman’s correlations, as appropriate. Regression analysis assessed relationships among metabolism, FA, cognitive performance and QA/KA.

Results: Clusters of reduced FA in SLE vs. HC were found in the superior longitudinal fasciculus (SLF, 0.32 +/- 0.03 vs. 0.36 +/- 0.05, p=0.046), uncinate fasciculus (0.23 +/- 0.04 vs. 0.32 +/- 0.06, p=0.001) and SLF and corpus callosum combined (SLF/CC, 0.32 +/- 0.05 vs. 0.37 +/- 0.05, p=0.039), and WM tracts between clusters were diminished in SLE (Figure). Elevated QA/KA correlated with decreased FA in the CC (r = -0.58, p=0.040), the SLF/CC (r = -0.64, p=0.018) and with increased Simple Reaction Time (SRT, r = 0.72, p=0.006). The combination of elevated QA/KA and decreased FA in SLF/CC predicted worse SRT (R2=0.48, p=0.009). Elevated QA/KA correlated with decreased left premotor cortex (PMC) metabolism (r = -0.61, p=0.021) and increased SRT (r = 0.74, p=0.003). The combination of elevated QA/KA and decreased left PMC metabolism predicted worse SRT (R2=0.73, p< 0.001).

Conclusion: Elevated QA/KA ratios correlated with decreased PMC metabolism and WMI in fronto-parietal pathways, suggesting neuronal and associated WM damage. The combination of elevated QA/KA and abnormalities in these brain regions correlated with increased SRT, a measure of visuomotor processing speed and attention. These results, which require validation in a larger longitudinal cohort, suggest a role for QA, and associated neurotoxicity, in CD in SLE.

Supporting image 1

Table: Demographics and characteristics of SLE subjects and healthy controls (HC) who underwent FDG-PET and DTI. Comparisons are between the 14 SLE subjects who underwent FDG-PET imaging (13 of these subjects also underwent DTI imaging) and 5 HC. All data is reported either as a mean (or median where indicated) +/- standard deviation (or interquartile range), or as a frequency (%). All data refers to that which was collected at the time of evaluation.

Supporting image 2

Figure: Group Tractography Displays Abnormal White Matter Pathways in SLE. SLE subjects demonstrated decreased fractional anisotropy (FA) in 4 of 5 previously identified abnormal FA clusters in SLE.[3] The images shown represent reconstructed white matter tracts between clusters of decreased white matter microstructural integrity (decreased FA). The percent reduction in white matter tract numbers in SLE versus HC is displayed.

References:
1. Schwarcz R and Stone TW. The kynurenine pathway and the brain: Challenges, controversies and promises. Neuropharmacology 2017;112:237_247.
2. Anderson EW, Fishbein J, Hong J, et al. Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus. Lupus Sci Med 2021;8.
3. Mackay M, Vo A, Tang CC, et al. Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. JCI Insight 2019;4.


Disclosures: E. Anderson, None; C. Tang, None; A. Vo, None; C. Aranow, None; B. Volpe, None; B. Diamond, None; M. Mackay, None.

To cite this abstract in AMA style:

Anderson E, Tang C, Vo A, Aranow C, Volpe B, Diamond B, Mackay M. Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/quinolinic-acid-a-kynurenine-tryptophan-pathway-metabolite-correlates-with-abnormalities-in-brain-structure-and-function-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quinolinic-acid-a-kynurenine-tryptophan-pathway-metabolite-correlates-with-abnormalities-in-brain-structure-and-function-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology